Infliximab-Induced Erythema Multiforme in a Patient with Chronic Sarcoidosis

Andreas Afthinos; Aggeliki Pandi; Maria Horti; Ilias C. Papanikolaou

doi:10.5603/ARM.2020.0131

You are currently viewing a new version of our website. To view the old version click .

Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.

Letter

18 July 2020

Infliximab-Induced Erythema Multiforme in a Patient with Chronic Sarcoidosis

and

Pulmonary Department, Corfu General Hospital, Kontokali, Greece

Pathology Unit, Sismanoglio General Hospital, Marousi, Greece

Author to whom correspondence should be addressed.

Adv. Respir. Med.2020, 88(3), 289-291;https://doi.org/10.5603/ARM.2020.0131

Version Notes

Order Reprints

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Tumor Necrosis Factor-α (TNF-α) inhibitors, in particular infliximab, have shown effectiveness as a third-line treatment option in relapsing, refractory sarcoidosis that requires an increased dose of corticosteroids plus one or more anti-sarcoidosis disease modifying drugs [...]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Relative Lymphocytosis in COVID-19—A Ray of Hope

Diagnosis of Sarcoidosis—The Updated ATS 2020 Recommendations through the Prism of Everyday Clinical Practice